Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이동윤 | - |
dc.date.accessioned | 2019-12-03T00:39:26Z | - |
dc.date.available | 2019-12-03T00:39:26Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.citation | JOURNAL OF CONTROLLED RELEASE, v. 268, page. 305-313 | en_US |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.issn | 1873-4995 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0168365917308179?via%3Dihub | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/116580 | - |
dc.description.abstract | The number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies. | en_US |
dc.description.sponsorship | This study was supported by a grant from the National Leading Research Laboratory (NRF-2015R1A2A1A05001832) through the National Research Foundation of Korea (NRF) funded by the Korean Government. This study was also supported by a grant from the Basic Science Research Program (2015R1D1A1A09060567, NRF-2014R1A2A2A03004802) through the National Research Foundation of Korea (NRF) funded by Korea Government. This study was also supported by a grant from the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C2099). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER SCIENCE BV | en_US |
dc.subject | Diabetes | en_US |
dc.subject | Peptide nanoparticle | en_US |
dc.subject | Oral delivery | en_US |
dc.subject | Hypoglycemia | en_US |
dc.subject | Anti-obesity | en_US |
dc.title | Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes | en_US |
dc.type | Article | en_US |
dc.relation.volume | 268 | - |
dc.identifier.doi | 10.1016/j.jconrel.2017.08.035 | - |
dc.relation.page | 305-313 | - |
dc.relation.journal | JOURNAL OF CONTROLLED RELEASE | - |
dc.contributor.googleauthor | Nurunnabi, Md | - |
dc.contributor.googleauthor | Lee, Seung-Ah | - |
dc.contributor.googleauthor | Revuri, Vishnu | - |
dc.contributor.googleauthor | Hwang, Yong Hwa | - |
dc.contributor.googleauthor | Kang, Sung Hun | - |
dc.contributor.googleauthor | Lee, Minhyung | - |
dc.contributor.googleauthor | Cho, Sungpil | - |
dc.contributor.googleauthor | Cho, Kwang Jae | - |
dc.contributor.googleauthor | Byun, Youngro | - |
dc.contributor.googleauthor | Bae, You Han | - |
dc.relation.code | 2017003061 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | dongyunlee | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.